Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression

• Published in: Journal of clinical medicine 2024-08, Vol.13 (15), p.4531
• Main Authors: Smok-Kalwat, Jolanta, Mertowska, Paulina, Mertowski, Sebastian, Góźdź, Stanisław, Grywalska, Ewelina
• Format: Article
• Language: English
• Subjects: Biopsy; Breastfeeding & lactation; Bronchoscopy; Cancer therapies; Development and progression; Diagnosis; Disease prevention; Health aspects; Immune system; Lung cancer; Medical prognosis; Medical research; Patients; Physiological aspects; Risk factors; Smoking; Squamous cell carcinoma; Tobacco; Toll-like receptors; Tumors
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13154531

Lung squamous cell carcinoma (SCC) is one of the major subtypes of lung cancer, characterized by diverse molecular pathways and variable clinical outcomes. This study focused on assessing the levels of TLR-2, TLR-3, TLR-4, TLR-7, TLR-8, and TLR-9 on peripheral blood lymphocytes in patients with newly diagnosed SCC compared to a group of healthy controls, in the context of disease development and patient survival, conducted over three years. The study aimed to investigate the differences in TLR expression between SCC patients and healthy people and to understand their role in the development of the disease and patient survival over three years. The study included the assessment of TLR-2, TLR-3, TLR-4, TLR-7, TLR-8, and TLR-9 levels on peripheral blood lymphocytes in patients with newly diagnosed SCC and in the control group. The expression of TLRs was measured using flow cytometry, and the soluble forms of the tested TLRs were measured using enzyme-linked immunosorbent assays. All the analyses were conducted over a three-year period from the time patients were recruited to the study. The obtained test results were statistically analyzed. Results showed statistically significant differences in TLR expression between the groups, with higher TLR levels correlating with an advanced stage of disease and poorer survival rates. This suggests that the deregulation of TLR levels may be involved in promoting tumor development and influencing its microenvironment. The research, conducted over three years, indicates the need for further research on the role of TLRs in SCC, including their potential use as therapeutic targets and biomarkers. This may help to increase the effectiveness of standard treatments and improve clinical outcomes in patients with SCC.